Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Cue Biopharma (NASDAQ: CUE) Hits All Primary Endpoints in CUE-221 Chronic Hives Trial, Stock Still Falls 24%

Chronic spontaneous urticaria is a condition marked by recurring hives and swelling with no identifiable external trigger, and it can persist for months or years, significantly affecting patients' quality of life. Current treatment options, including the widely used antibody therapy omalizumab, don't work for …

Nitish Kishor | 22 September 2026

Viking Therapeutics (NASDAQ: VKTX) Weight-Loss Drug VK2735 Holds Up in New Obesity Trial Data

That matters because dosing convenience has become almost as important as raw efficacy in this category. GLP-1 and dual-agonist obesity drugs already work — the market has largely moved on to asking which ones patients will actually stick with. A treatment that lets people …

Nitish Kishor | 22 September 2026

Moderna (NASDAQ: MRNA) Stock Jumps 12% Ahead of Late-Breaking Melanoma Vaccine Data at ESMO 2026

The therapy itself represents one of the more scientifically ambitious applications of mRNA technology outside of infectious disease. Intismeran autogene is built as a personalized neoantigen therapy, meaning each patient's vaccine is manufactured based on the specific genetic mutations found in their own tumor. …

Nitish Kishor | 22 September 2026

MindWalk Holdings (NASDAQ: HYFT) Stock Rises 8% on OpenFold3 Deployment Cutting Inference Latency 5X

For context, antibody-antigen inference refers to computational modeling of how antibodies — the immune system's targeting molecules — interact with antigens, the molecular structures they bind to. This kind of modeling sits at the center of modern computational drug discovery, particularly forBiologicsand antibody-based therapeutics, …

Nitish Kishor | 22 September 2026

Lexeo Therapeutics (NASDAQ: LXEO) Buys Mantle Therapeutics to Widen Friedreich Ataxia Pipeline

The logic behind the deal isDiversificationwithin a single indication. Lexeo's existing flagship program, LX2006, is a gene therapy, a one-time treatment approach that works by delivering a functional copy of a gene directly into cells. The MantleAssetstake entirely different mechanisms: an oral drug that …

Nitish Kishor | 22 September 2026

GRAIL (NASDAQ: GRAL) Stock Soars 34% After FDA Briefing Documents Back Galleri Cancer Test

FDA advisory committee briefing documents are prepared by the agency's own staff in advance of a public meeting where outside experts vote on and discuss a product's benefit-risk profile. While these documents don't represent a final regulatory decision, they often set the tone for …

Nitish Kishor | 22 September 2026

Stock Yards Bancorp Director Reports Share Acquisition

Edwin S. Saunier, a director of Stock Yards Bancorp, Inc. (NASDAQ:SYBT), filed a Form 4 on September 22, 2026, disclosing a purchase of common stock on September 21, 2026, held indirectly through a Director Deferred Compensation Plan trust.

Vinay Lochav | 22 September 2026

Stock Yards Bancorp Director Acquires 124 Shares

A Form 4 filed with the SEC on September 22, 2026, discloses that Stephen M. Priebe, a director of Stock Yards Bancorp, Inc. (NASDAQ:SYBT), acquired 124 shares of common stock on September 21, 2026, through the company's Directors' Deferred Comp Plan trust.

Nitish Kishor | 22 September 2026

Horizon Kinetics Buys 756 Shares of RENN Fund

Horizon Kinetics Asset Management LLC filed a Form 4 with the SEC on September 22, 2026, disclosing a purchase of 756 shares of common stock in RENN Fund, Inc. (NYSE:RCG) on September 21, 2026.

Aakashdeep | 22 September 2026

Nayax CTO David Ben-Avi Buys 1,014 Ordinary Shares

David Ben-Avi, CTO and Co-Founder of Nayax Ltd. (NASDAQ:NYAX), filed a statement of changes in beneficial ownership on September 22, 2026, reporting an open-market purchase of ordinary shares on September 17, 2026.

Manish Choudhary | 22 September 2026
Support

Hi! How can we help you today?

Loading…